New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - simvastatin 10mg;  ;  ;  ;   - film coated tablet - 10 mg - active: simvastatin 10mg         excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd. in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), i.e. patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, simvastatin is indicated to: · reduce the risk of total mortality by reducing chd deaths. · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures. · reduce the risk of stroke. · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty). · reduce the need for peripheral and other non-coronary revascularisation procedures. · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, simvastatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers. in hypercholesterolaemic patients with coronary heart disease, simvastatin slows the progress of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - simvastatin 20mg;  ;  ;  ;   - film coated tablet - 20 mg - active: simvastatin 20mg         excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd. in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), i.e. patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, simvastatin is indicated to: · reduce the risk of total mortality by reducing chd deaths. · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures. · reduce the risk of stroke. · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty). · reduce the need for peripheral and other non-coronary revascularisation procedures. · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, simvastatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers. in hypercholesterolaemic patients with coronary heart disease, simvastatin slows the progress of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - simvastatin 40mg;  ;  ;  ;   - film coated tablet - 40 mg - active: simvastatin 40mg         excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd. in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), i.e. patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, simvastatin is indicated to: · reduce the risk of total mortality by reducing chd deaths. · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures. · reduce the risk of stroke. · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty). · reduce the need for peripheral and other non-coronary revascularisation procedures. · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, simvastatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers. in hypercholesterolaemic patients with coronary heart disease, simvastatin slows the progress of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - simvastatin 80mg;  ;  ;  ;   - film coated tablet - 80 mg - active: simvastatin 80mg         excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd. in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), i.e. patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, simvastatin is indicated to: · reduce the risk of total mortality by reducing chd deaths. · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures. · reduce the risk of stroke. · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty). · reduce the need for peripheral and other non-coronary revascularisation procedures. · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, simvastatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers. in hypercholesterolaemic patients with coronary heart disease, simvastatin slows the progress of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - tenofovir disoproxil succinate 300.6mg equivalent to tenofovir disoproxil 245 mg;   - film coated tablet - 245 mg - active: tenofovir disoproxil succinate 300.6mg equivalent to tenofovir disoproxil 245 mg   excipient: croscarmellose sodium indigo carmine aluminium lake lactose macrogol 3350 magnesium stearate microcrystalline cellulose polyvinyl alcohol pregelatinised maize starch purified talc purified water titanium dioxide - tenofovir disoproxil tablets in combination with other antiretroviral agents are indicated for the treatment of hiv-infected adults and paediatric patients 12 years of age and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - dexmedetomidine hydrochloride 118 µg/ml (equiv 100 µg/ml dexmedetomidine) - concentrate for infusion - 100 mcg/ml - active: dexmedetomidine hydrochloride 118 µg/ml (equiv 100 µg/ml dexmedetomidine) excipient: sodium chloride water for injection - for sedation of initially intubated patients during treatment in an intensive care setting. the use of dexmedetomidine-teva by continuous intubation in these patents should not exceed 24 hours. for sedation of non-intubated patients prior to and/or during surgical and other procedures.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg (anhydrous);  ;  ; citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg (anhydrous) - film coated tablet - 20 mg - active: citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg (anhydrous)     excipient: colloidal silicon dioxide hypromellose macrogol 6000 magnesium stearate mannitol microcrystalline cellulose titanium dioxide active: citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg (anhydrous) excipient: colloidal silicon dioxide magnesium stearate mannitol microcrystalline cellulose opadry white 03f28539 - treatment of depressive illness in the initial phase and as maintenance against potential relapse or recurrence.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - sumatriptan succinate 100mg (140 mg as the succinate) - tablet - 100 mg - active: sumatriptan succinate 100mg (140 mg as the succinate) excipient: croscarmellose sodium   iron oxide red lactose magnesium stearate   microcrystalline cellulose   purified water - sumatriptan is indicated for acute relief of migraine attacks with or without aura.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - sumatriptan succinate 50mg (70 mg as the succinate) - tablet - 50 mg - active: sumatriptan succinate 50mg (70 mg as the succinate) excipient: croscarmellose sodium   lactose magnesium stearate   microcrystalline cellulose   purified water - sumatriptan is indicated for acute relief of migraine attacks with or without aura.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - clonidine hydrochloride 25ug - tablet - 25 mcg - active: clonidine hydrochloride 25ug excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc sodium starch glycolate - the prophylactic management of migraine or recurrent vascular headaches in adult patients. the management of vasomotor conditions commonly associated with the menopause and characterised by flushing.